Views & Analysis Medical affairs: learning to change behaviour? Research points to the need for greater engagement with behavioural science among medical affairs professionals.
Views & Analysis New research: can pharma get healthy rewards for good behavi... Research shows industry needs to see more evidence of success for wider adoption.
Views & Analysis Behavioural science + medical education: a transformative co... ‘We need to walk in the shoes of HCPs and patients if we are to design programmes that improve health outcomes.’
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
